Estamos no ar no ! Saiba mais
Deslistada

HGEN foi retirado da bolsa em 25 de julho de 2023.

 

Sobre: Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.

Funcionários: 6

Notícias

Positiva
Neutra
Negativa
Sentimento 3 meses
Positiva 0%
Neutra 0%
Negativa 0%

Não recebemos notícias recentes sobre HGEN

Gráficos de preços implementados com Lightweight Charts™